AccessibilityHelpAbout Us
Fisher & Paykel Healthcare logo

Fisher & Paykel Healthcare(ASX) FPH

Market CapA$20.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+3,271%
5 Year+24%
1 Year+7%
1 Month-2%
A$35.74
+1.51%
+0.53Today
Fisher & Paykel Healthcare last closing stock price
MetricPriceDate
Last closeAUD 35.742026-09-21
Fisher & Paykel Healthcare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.53%AUD 35.202026-09-14
1 month-1.57%AUD 36.312026-08-21
3 month+15.81%AUD 30.862026-06-23
Year to date+10.75%AUD 32.272025-12-31
1 year+7.07%AUD 33.382025-09-19
3 year+86.63%AUD 19.152023-09-22
5 year+23.6%AUD 28.922021-09-22
Since inception+3,270.82%AUD 1.042001-11-21

Fisher & Paykel Healthcare Financials at a Glance

Market Cap

A$20.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

NZ$4.57B

Net Income (TTM)

NZ$999.04M

EPS (TTM)

A$0.70

P/E Ratio

49.77

Dividend

A$0.51

Beta (Volatility)

-0.01 (Low)

Price

A$35.74

Volume

268,216

Open

A$34.86

Previous Close

A$35.74

Daily Range

A$34.86 - A$35.88

52-Week Range

A$26.47 - A$37.71

Estimated Earnings Date

Nov 24, 2026

FPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare Corporation Limited is a global innovator in medical device technology, specializing in the design, production, and distribution of advanced products for respiratory care and sleep apnea treatment. Established in 1934 and headquartered in Auckland, New Zealand, the company serves both clinical and homecare environments.

Products and Services
  • Airvo 2: A humidified nasal high flow system for respiratory support
  • Optiflow: Designed for nasal high flow therapy in various settings
  • F&P 850 System: Offers both non-invasive and invasive ventilation capabilities
Growth Outlook
  • Increasing demand for respiratory care solutions drives market expansion
  • Investment in R&D enhances product innovation and competitive edge
  • Global healthcare trends favor homecare solutions, boosting sales potential
Financial Highlights
  • Recent quarterly revenue of NZD 1.25 billion reflects strong market performance
  • Net income for the latest quarter reached NZD 257 million, showcasing profitability
  • TTM gross profit margin stands at 64.16%, indicating operational efficiency
Fisher & Paykel Healthcare has established itself as a leader in the medical device industry, particularly in respiratory care and sleep apnea treatment. The company's innovative products, such as the Airvo 2 and Optiflow, cater to a growing global demand for effective respiratory solutions. With a strong focus on research and development, Fisher & Paykel is well-positioned to capitalize on emerging healthcare trends, particularly the shift towards homecare solutions. Recent financial performance highlights the company's robust revenue generation and profitability, making it an attractive option for potential investors interested in the healthcare sector.
AI Generated • Aug 23, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

7,661

CEO

Lewis George Gradon

Website

www.fphcare.com

Headquarters

Auckland, AUK 2013, NZ

FPH Financials

Key Financial Metrics (TTM)

Gross Margin

64.16%

Operating Margin

28.52%

Net Income Margin

20.03%

Return on Equity

22.84%

Return on Capital

29.49%

Return on Assets

16.42%

Earnings Yield

2.01%

Dividend Yield

1.45%

Payout Ratio

53.85%

Stock Overview

Market Cap

A$20.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

588.25M

Volume

268.22K

Avg. Volume

363.80K

Financials (TTM)

Gross Profit

NZ$2.62B

Operating Income

NZ$514.38M

EBITDA

NZ$1.75B

Operating Cash Flow

NZ$1.21B

Capital Expenditure

-NZ$247.28M

Free Cash Flow

NZ$966.00M

Cash & ST Invst.

NZ$464.46M

Total Debt

NZ$147.16M

Fisher & Paykel Healthcare Performance Analysis

Fisher & Paykel Healthcare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31NZD 1,447,524,078-6.5%
20242024-03-31NZD 1,629,840,15412.6%
20252025-03-31NZD 1,841,976,74313.0%
20262026-03-31NZD 2,078,426,78512.8%
Fisher & Paykel Healthcare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-301.3%
Q42025-03-3134.6%
Q22025-09-30-14.7%
Q42026-03-3114.2%
Fisher & Paykel Healthcare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31NZD 0.39-36.0%
20242024-03-31NZD 0.21-46.5%
20252025-03-31NZD 0.58177.4%
20262026-03-31NZD 0.7021.1%
Fisher & Paykel Healthcare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30504.7%
Q42025-03-31146.2%
Q22025-09-30-43.8%
Q42026-03-3122.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

NZ$1.25B

+32.8%

Gross Profit

NZ$808.75M

+44.9%

Gross Margin

64.83%

N/A

Market Cap

A$20.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.80M

N/A

Employees

7,396

N/A

Net Income

NZ$257.36M

+917.2%

EBITDA

NZ$455.79M

+85.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

NZ$464.46M

+466.4%

Total Debt

NZ$147.16M

-22.2%

Accounts Receivable

NZ$345.30M

+34.3%

Inventory

NZ$329.68M

+2.9%

Long Term Debt

NZ$113.74M

+22.4%

Short Term Debt

NZ$32.80M

-65.9%

Return on Assets

16.42%

N/A

Return on Invested Capital

28.31%

N/A

Free Cash Flow

NZ$298.76M

+35.7%

Operating Cash Flow

NZ$420.44M

+54.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PME.AXPro Medicus Limited
A$165.57-2.36%
SHL.AXSonic Healthcare Limited
A$19.47+1.20%
COH.AXCochlear Limited
A$140.95+5.27%
ANN.AXAnsell Limited
A$42.71+0.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
GRMLGreenland Mines
$7.61+166.84%
INTCIntel
$115.97+6.79%
IBITiShares Bitcoin Trust
$48.08+4.47%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$38.95-6.12%

Questions About FPH

What is the current price of Fisher & Paykel Healthcare?

Fisher & Paykel Healthcare is trading at A$35.74 per share.

What is the 52-week range for Fisher & Paykel Healthcare?

Over the past 52 weeks, Fisher & Paykel Healthcare has traded between A$26.47 and A$37.71.

How much debt does Fisher & Paykel Healthcare have?

As of the most recent reporting period, Fisher & Paykel Healthcare reported total debt of NZ$121.69M.

How much cash does Fisher & Paykel Healthcare have on hand?

Fisher & Paykel Healthcare reported NZ$384.05M in cash and cash equivalents in its most recent financial results.

What is Fisher & Paykel Healthcare’s dividend yield?

Fisher & Paykel Healthcare currently has a dividend yield of 1.45%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services